Transport & Storage Of Antibody Drug Conjugates (ADCs)

By Brian Moloney, Chief Commercial Officer (CCO)

Antibody-drug conjugates (ADCs) represent a significant advancement in biopharmaceuticals, offering highly targeted and effective cancer treatment. However, their cytotoxic nature and complex manufacturing process necessitate stringent safety measures during handling, storage, and transportation. As ADCs often pass through multiple specialized facilities, ensuring safe handling and preventing product loss are critical challenges. Single-use technologies provide a compelling solution by creating closed, sterile systems that enhance safety and streamline operations. These systems not only reduce the risk of contamination but also simplify logistics, making them increasingly popular in the biopharmaceutical industry.

For ADCs, maintaining ultra-cold temperatures during storage is essential to preserve stability and efficacy. Innovative solutions like Single Use Support’s RoSS.FRDG ultra-cold freezer offer precise temperature control, ensuring that ADCs are stored safely even in unexpected situations. Additionally, robust packaging solutions, such as RoSS® shell and RoSS.SHIP®, safeguard ADCs during shipping, providing secondary and tertiary protective layers that prevent leaks and maintain cold chain integrity. As the biopharmaceutical industry continues to adopt single-use technologies, these innovations are poised to enhance both safety and efficiency, ultimately driving the success of ADC therapies.

Learn more by accessing the full article below.